{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T19:45:38Z","timestamp":1794080738070,"version":"4.8.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"am","delay-in-days":303,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.pnpbp.2020.110166","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T07:44:28Z","timestamp":1604562268000},"page":"110166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313"],"prefix":"10.1016","volume":"108","author":[{"given":"Priska","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Ort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Golor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Kornberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2020.110166_bb0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpsychires.2015.02.001","article-title":"Evaluating psychological interventions in a novel experimental human model of anxiety","volume":"63","author":"Ainsworth","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2020.110166_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bbr.2014.06.049","article-title":"Binge-like consumption of caloric and non-caloric palatable substances in ad libitum-fed C57BL\/6J mice: pharmacological and molecular evidence of orexin involvement","volume":"272","author":"Alcaraz-Iborra","year":"2014","journal-title":"Behav. Brain Res."},{"issue":"6","key":"10.1016\/j.pnpbp.2020.110166_bb0015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0306-4530(01)00075-0","article-title":"Inhalation of 35% CO2 results in activation of the HPA axis in healthy volunteers","volume":"27","author":"Argyropoulos","year":"2002","journal-title":"Psychoneuroendocrinology."},{"key":"10.1016\/j.pnpbp.2020.110166_bb0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0269881106063889","article-title":"A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers","volume":"21","author":"Bailey","year":"2007","journal-title":"Journal of Psychopharmacology."},{"key":"10.1016\/j.pnpbp.2020.110166_bb0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0269881108089603","article-title":"A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety","volume":"23","author":"Bailey","year":"2009","journal-title":"Journal of Psychopharmacology"},{"issue":"9","key":"10.1016\/j.pnpbp.2020.110166_bb0030","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1177\/0269881111400650","article-title":"Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety","volume":"25","author":"Bailey","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110166_bb0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jcph.1588","article-title":"Impact of the selective Orexin-1 receptor antagonist ACT-539313 on the pharmacokinetics of the CYP3A probe drug midazolam in healthy male subjects","volume":"60","author":"Berger","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110166_bb0040","first-page":"1","article-title":"Impact of the selective Orexin-1 receptor antagonist ACT-539313 on the pharmacokinetics of the CYP3A probe drug midazolam in healthy male subjects","volume":"00","author":"Berger","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110166_bb0045","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1152\/japplphysiol.00700.2012","article-title":"A unified survival theory of the functioning of the hypocretinergic system","volume":"115","author":"Chase","year":"2013","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.pnpbp.2020.110166_bb0050","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/bcp.13204","article-title":"Pharmacodynamic response profiles of anxiolytic and sedative drugs","volume":"83","author":"Chen","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110166_bb0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/0269881107082108","article-title":"Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA a \u03b1 2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers","volume":"22","author":"de Haas","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2020.110166_bb0060","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0269881108092595","article-title":"The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A 2,3 selective agonist, in comparison with lorazepam in healthy volunteers","volume":"23","author":"de Haas","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110166_bb0065","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2020.110166_bb0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0269881112443742","article-title":"Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic","volume":"27","author":"Diaper","year":"2013","journal-title":"Journal of Psychopharmacology."},{"issue":"07","key":"10.1016\/j.pnpbp.2020.110166_bb0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5414\/CPP39293","article-title":"Midazolam and cortisol metabolism before and after CYP3A induction in humans","volume":"39","author":"Eeckhoudt","year":"2001","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.pnpbp.2020.110166_bb0080","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.janxdis.2012.07.009","article-title":"Pharmacological treatment of anxiety disorders: current treatments and future directions","volume":"26","author":"Farach","year":"2012","journal-title":"Journal of Anxiety Disorders."},{"issue":"11","key":"10.1016\/j.pnpbp.2020.110166_bb0085","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1177\/0091270010387141","article-title":"Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?","volume":"51","author":"Friedman","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2020.110166_bb0090","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00228-003-0690-3","article-title":"Urinary 6\u03b2-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals","volume":"59","author":"Galteau","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110166_bb0095","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.pnpbp.2020.110166_bb0100","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/009286159502900324","article-title":"Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry\/pharmacokinetics UK joint working party","volume":"29","author":"Gough","year":"1995","journal-title":"Drug Information Journal."},{"issue":"4","key":"10.1016\/j.pnpbp.2020.110166_bb0105","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","article-title":"Orexin receptor antagonists as emerging treatments for psychiatric disorders","volume":"36","author":"Han","year":"2020","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.pnpbp.2020.110166_bb0110","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/0269881112448946","article-title":"Orexin receptor antagonism: an ascending multiple-dose study with almorexant","volume":"26","author":"Hoever","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110166_bb0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nm.2075","article-title":"A key role for orexin in panic anxiety","volume":"16","author":"Johnson","year":"2010","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.pnpbp.2020.110166_bb0120","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/npp.2012.38","article-title":"Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia","volume":"37","author":"Johnson","year":"2012","journal-title":"Neuropsychopharmacology."},{"issue":"5","key":"10.1016\/j.pnpbp.2020.110166_bb0125","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.physbeh.2012.04.016","article-title":"Orexin 1 receptors are a novel target to modulate panic responses and the panic brain network","volume":"107","author":"Johnson","year":"2012","journal-title":"Physiol. Behav."},{"issue":"9","key":"10.1016\/j.pnpbp.2020.110166_bb0130","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/da.22403","article-title":"Orexin-1 and -2 receptor involvement in CO2-induced panic-associated behavior and autonomic responses","volume":"32","author":"Johnson","year":"2015","journal-title":"Depression and Anxiety."},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110166_bb0135","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/bcp.14251","article-title":"First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist","volume":"86","author":"Kaufmann","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110166_bb0140","first-page":"1","article-title":"First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist","author":"Kaufmann","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.110166_bb0145","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.0953-8194.2004.01158.x","article-title":"Acute carbon dioxide exposure in healthy adults: evaluation of a novel means of investigating the stress response","volume":"16","author":"Kaye","year":"2004","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.pnpbp.2020.110166_bb0150","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0009-9236(98)90084-4","article-title":"Urinary excretion of 6\u03b2-hydroxycortisol an in vivo marker for CYP3A induction: applications and recommendations","volume":"63","author":"Kovacs","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.pnpbp.2020.110166_bb0155","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1208\/s12248-017-0090-8","article-title":"Distribution of exogenous and endogenous CYP3A markers and related factors in healthy males and females","volume":"19","author":"Lee","year":"2017","journal-title":"AAPS J."},{"issue":"10","key":"10.1016\/j.pnpbp.2020.110166_bb0160","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/00498254.2017.1390628","article-title":"The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation","volume":"48","author":"Lin","year":"2018","journal-title":"Xenobiotica."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110166_bb0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jchromb.2009.11.023","article-title":"Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS\/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity","volume":"878","author":"Lutz","year":"2010","journal-title":"J. Chromatogr. B"},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110166_bb0170","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain","volume":"435","author":"Marcus","year":"2001","journal-title":"J. Comp. Neurol."},{"issue":"26","key":"10.1016\/j.pnpbp.2020.110166_bb0175","article-title":"Orexin 1 receptor antagonists in compulsive behaviour and anxiety: possible therapeutic use","volume":"8","author":"Merlo-Pich","year":"2014","journal-title":"Frontiers in Neuroscience"},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110166_bb0180","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.euroneuro.2019.05.009","article-title":"Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration","volume":"29","author":"Muehlan","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2020.110166_bb0185","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/0269881108097716","article-title":"The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures","volume":"24","author":"Papadopoulos","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.110166_bb0190","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0165-0327(94)00088-Q","article-title":"35% CO2 challenge in panic and mood disorders","volume":"33","author":"Perna","year":"1995","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.pnpbp.2020.110166_bb0195","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/13543784.2014.996286","article-title":"Novel investigational therapeutics for panic disorder","volume":"24","author":"Perna","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"9","key":"10.1016\/j.pnpbp.2020.110166_bb0200","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/npp.2012.48","article-title":"Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats","volume":"37","author":"Piccoli","year":"2012","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pnpbp.2020.110166_bb0205","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110166_bb0210","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0269881110364270","article-title":"Effects of 7.5% CO2 challenge in generalized anxiety disorder","volume":"25","author":"Seddon","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2020.110166_bb0215","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/clpt.2013.128","article-title":"Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance","volume":"94","author":"Shin","year":"2013","journal-title":"Clinical Pharmacology & Therapeutics."},{"issue":"6","key":"10.1016\/j.pnpbp.2020.110166_bb0220","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/cmdc.201300003","article-title":"Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist","volume":"8","author":"Steiner","year":"2013","journal-title":"ChemMedChem."},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2020.110166_bb0225","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-5793(98)01266-6","article-title":"Distribution of orexin receptor mRNA in the rat brain","volume":"438","author":"Trivedi","year":"1998","journal-title":"FEBS Lett."},{"issue":"6","key":"10.1016\/j.pnpbp.2020.110166_bb0230","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1176\/ajp.144.6.788","article-title":"Reduction of CO2-induced anxiety in patients with panic attacks after repeated CO2 exposure","volume":"144","author":"van den Hout","year":"1987","journal-title":"Am. J. Psychiatr."},{"issue":"12","key":"10.1016\/j.pnpbp.2020.110166_bb0235","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1177\/0269881118791521","article-title":"Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects","volume":"32","author":"van der Ark","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.110166_bb0240","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0269881105051527","article-title":"CO2 challenge results in hypothalamic-pituitary-adrenal activation in healthy volunteers","volume":"19","author":"van Duinen","year":"2005","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2020.110166_bb0245","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1017\/S1461145706007358","article-title":"CO2 challenge induced HPA axis activation in panic","volume":"10","author":"van Duinen","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.110166_bb0250","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cpr.2011.12.004","article-title":"The 35% carbon dioxide test in stress and panic research: overview of effects and integration of findings","volume":"32","author":"Vickers","year":"2012","journal-title":"Clin. Psychol. Rev."},{"issue":"25","key":"10.1016\/j.pnpbp.2020.110166_bb0255","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1073\/pnas.0702676104","article-title":"Control of hypothalamic orexin neurons by acid and CO2","volume":"104","author":"Williams","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.pnpbp.2020.110166_bb0260","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bcpt.12492","article-title":"Relationships between endogenous plasma biomarkers of constitutive cytochrome P450 3A activity and single-time-point Oral midazolam microdose phenotype in healthy subjects","volume":"118","author":"Woolsey","year":"2016","journal-title":"Basic & Clinical Pharmacology & Toxicology."},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110166_bb0265","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40261-018-0650-4","article-title":"Safety, tolerability, and pharmacokinetics of Suvorexant: a randomized rising-dose trial in healthy men","volume":"38","author":"Yee","year":"2018","journal-title":"Clinical Drug Investigation."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620304826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620304826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:53:57Z","timestamp":1759521237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584620304826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":53,"alternative-id":["S0278584620304826"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110166","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110166"}}